Introduction
Each year, more than 50 000 new cases of bladder cancer are detected (Kozlowski, 1999) . Super®cial bladder cancers comprise 80% of these neoplasms and have a high rate of tumor recurrence despite treatment with transurethral resection and intravesical chemotherapy or immunotherapy (Kroft and Oyasu, 1994; Herr, 1997) . Tumor progression to more advanced disease occurs in up to 30 ± 40% of patients with high risk super®cial disease within 5 years (Herr, 1997; Cookson et al., 1997) . Moreover, 15 ± 34% of patients with super®cial bladder cancer will die of bladder cancer (Herr, 1997; Cookson et al., 1997) . The prognosis for patients with advanced bladder cancer is poor, despite aggressive multimodal therapy, and only 20 ± 40% of these patients survive 5 years (Warde and Gospodarowicz, 1997; Corral and Logothetis, 1997) . Thus, novel treatments are needed to improve the prognosis for patients with bladder cancer.
Multiple gene alterations are involved in the development and progression of bladder cancer. Cytogenetic studies have found a high rate of loss of heterozygosity (LOH) in chromosome 9 in lowgrade, low-stage bladder cancer (Kroft and Oyasu, 1994) . Previous analyses have suggested that the inactivation of one or more putative tumor suppressor genes on chromosome 9, including p15 (INK4A), p16 (INK4B), and p14 (ARF) could be involved in abnormal uroepithelial proliferation and dierentiation in the early stages of bladder carcinogenesis (Kroft and Oyasu, 1994) . We have previously demonstrated that gelsolin, a regulator of the actin cytoskeleton mapped to chromosome 9q33, acts as a tumor suppressor in human bladder cancer cell lines both in vitro and in vivo (Tanaka et al., 1995) . Recently, LOH of chromosome 10q has also been reported in bladder cancer (Sandberg and Berger, 1994; Cappellen et al., 1997; Cairns et al., 1998; Aveyard et al., 1999) . MMAC1/PTEN/TEP1 has been identi®ed as a tumor suppressor gene mapped to chromosome 10q23 (Steck et al., 1997; Li and Sun, 1997; , and somatic mutations or deletions of MMAC1/PTEN have been found in bladder cancer as well as glioblastoma, melanoma, and cancers of the prostate, breast, endometrium, lung and thyroid (Steck et al., 1997; Wang et al., 1997; Gulberg et al., 1997; Cairns et al., 1997; Rhei et al., 1997; Tashiro et al., 1997; Kim et al., 1998; Dahia et al., 1997; Sano et al., 1999) . Additionally, germ-like mutations of MMAC1/PTEN have been demonstrated in Cowden disease, Bannayan-Zonana syndrome related hamartoma, and familial cancer predisposition syndromes Starink et al., 1986; Nelen et al., 1997; Marsh et al., 1997) . To date, however, the molecular and functional analyses of MMAC1/PTEN in bladder cancer have been very limited.
The initial identi®cation of MMAC1/PTEN as a phosphatase suggested its functional role as a regulator of mitogenic signaling pathways. Speci®cally, MMAC1/PTEN acts as a phosphatidylinositol phosphatase with a possible role in phosphatidylinositol 3'-kinase (PI3'K)-mediated signal transduction. Re-introduction of MMAC1/PTEN into de®cient cells inhibits the activation of Akt/PKB, a serine-threonine kinase (Davies et al., 1999a,b) . Akt/PKB has been shown to be involved in a variety of proliferative metabolic and anti-apoptotic pathways that are dependent upon PI3'K signaling for activation.
In this study, we examined the eect of MMAC1/ PTEN on human bladder cancer cells and document the novel ®nding that MMAC1/PTEN expression restores chemosensitivity in a doxorubicin resistant human bladder cancer cell subline with activated Akt/ PKB.
Results
Detection of MMAC1/PTEN and phosphorylated Akt/PKB in human bladder cancer cells
We used UM-UC-3 and T24 bladder cancer cell lines for adenoviral infection because UM-UC-3 has deletions from exons 3 to 9, and T24 has a nonsense mutation and a missense mutation for AAC (Asn) to ATC (Ile) at codons 44 and 48, respectively, in MMAC1/PTEN (Liu et al., 2000) . Expression of MMAC1/PTEN was seen in UM-UC-6, which has wild-type MMAC1/PTEN, but not in UM-UC-3 (Figure 1 ). T24 cells expressed an abnormal MMAC1/PTEN protein due to the known MMAC1/ PTEN mutation in these cells. Phosphorylated Akt/ PKB was expressed in both UM-UC-3 and T24, but not in UM-UC-6. These results are consistent with the low phosphatidylinositol phosphatase activity associated with expression of MMAC1/PTEN and high phosphorylated-Akt/PKB activity in UM-UC-3 and T24 cell lines resulting from MMAC1/PTEN deletion or mutation.
Effect of MMAC1/PTEN overexpression via adenovirus vector in human bladder cancer cells
The infectivity of UM-UC-3 was 460% and 490% infected cells at 25 and 50 multiplicity of infection (MOI), respectively, using an adenovirus vector expressing the enhanced green¯uorescent protein (Ad-GFP) followed by¯uorescence microscopy. To induce 470% infected cells with Ad-GFP in T24 and UM-UC-6dox bladder cancer cells, a higher MOI (200 MOI) was required. To examine the eects of MMAC1/PTEN on PI3'K-mediated signal transduction pathways, UM-UC-3, T24 and UM-UC-6dox bladder cancer cells were infected with either a recombinant adenovirus containing wild-type MMAC1/PTEN or a control GFP adenovirus and then treated with or without epidermal growth factor (EGF) after a period of serum deprivation. The phosphorylation status of Akt/PKB was then determined. Overexpression of MMAC1/PTEN via an adenoviral vector resulted in a dose dependent and speci®c inhibition of Akt/PKB phosphorylation at both activating residues of Akt/PKB (Thr-308 and Ser-473) in UM-UC-3 ( Figure 2a ) and T24 ( Figure 2b ) compared to mock-treated cells or cells treated with Ad-GFP. MMAC1/PTEN expression decreased EGFinduced Akt/PKB phosphorylation in UM-UC-3 and T24 cells, as did wortmannin, a PI3'K inhibitor. Some activation (phosphorylation) of Akt/PKB was observed in UM-UC-3 and T24 cells infected with control Ad-GFP following the stress of adenoviral infection.
In vitro growth suppression of human bladder cancer cells by Ad-MMAC
To determine the eect of MMAC1/PTEN on cell growth, bladder cancer cells were infected with Ad-MMAC or control Ad-GFP or mock-treated in vitro. Exogenous introduction of MMAC1/PTEN via an adenovirus vector inhibited the growth of both UM-UC-3 ( Figure 3a ) and T24 ( Figure 3b ) cells compared with mock-or Ad-GFP-infected cells. Increasing doses of viral infection were associated with a greater degree of growth inhibition. The numbers of UM-UC-3 and T24 cells were reduced 4 days or later after infection with Ad-MMAC by about 40% and 450%, respectively, compared with cells infected with the control Ad-GFP at the same doses. In addition, both the UM-UC-3 and T24 cells infected with Ad-MMAC grew at a higher saturation density and with a changed morphology compared with mock-or Ad-GFP-treated cells (data not shown). 
Chemosensitization to doxorubicin in human bladder cancer cells by Ad-MMAC
Expression of phosphorylated Akt/PKB and reduced expression of MMAC1/PTEN were observed in the doxorubicin resistant UM-UC-6dox bladder cancer cell line compared with the parental UM-UC-6 cells ( Figure 5a ). Introduction of MMAC1/PTEN via adenovirus vector inhibited Akt/PKB phosphorylation in the UM-UC-6dox cells (Figure 5b) . Furthermore, MMAC1/PTEN gene therapy of UM-UC-6dox cells at both 100 and 200 MOI increased sensitivity to doxorubicin compared with mock-or Ad-GFP treated cells (Figure 6a ). Treatment with 2 mg/ml of doxorubicin and Ad-MMAC infection of UM-UC-6dox resulted in a synergistic cytotoxic eect (Figure 6b ).
Discussion
In bladder cancer, LOH of chromosome 10q is more frequent in muscle-invasive tumors (Sandberg and Berger, 1994; Cappellen et al., 1997; Cairns et al., 1998; Aveyard et al., 1999) . The tumor suppressor gene MMAC1/PTEN has been mapped to 10q23, suggesting that inactivation of this gene may be involved in bladder cancer progression (Sandberg and Berger, 1994; Cappellen et al., 1997; Aveyard et al., 1999) . Inactivation of MMAC1/PTEN appears to be an early event in endometrial carcinogenesis (Maxwell et al., 1998; Levine et al., 1998) . However, cytogenetic and molecular analyses have demonstrated that in bladder cancer, as in glioblastoma, prostate cancer and several other cancers, chromosome 10q and mutations aecting the MMAC1/PTEN gene are predominantly detected in higher stage disease Aveyard et al., 1999; Wang et al., 1997; Guldberg et al., 1997; Whang et al., 1998; Suzuki et al., 1998) . It is possible that the functional loss of MMAC1/PTEN may be higher than that detected by LOH of chromosome 10q through gene alterations including mutations or deletions of MMAC1/PTEN and mechanisms such as translational modi®cation or hypermethylation in the promoter region. Identi®ca-tion of the mechanisms of action of MMAC1/PTEN may lead to further understanding of the mechanisms of bladder cancer progression and may identify novel targets for therapy. Cells were infected and then changed to serum-free medium 48 h later, followed by harvesting after another 24 h. EGF (50 ng/ml) treated-cells were stimulated with EGF for 15 min prior to harvest, whereas wortmannin treatment (1 mM) was administered for 30 min prior to stimulation
The role of MMAC1/PTEN in bladder cancer M Tanaka et al Recent studies showed that MMAC1/PTEN acts as a phosphatidylinositol phosphatase, suggesting a role in the PI3'K signaling pathways (Maehama and Dixon, 1998) . Akt/PKB, a serine-threonine kinase, has been shown to be associated with cell proliferation, particularly anti-apoptotic pathways that are dependent upon PI3'K signaling for activation (Aleesi and Cohen, 1998) . In this study, we demonstrated negative regulation of Akt/PKB activity and growth inhibition in bladder cancer cells by inducing the expression of the MMAC1/PTEN gene via an adenoviral vector. Although adenoviral infection with the MMAC1/ PTEN gene produces apoptosis in glioblastoma and prostate cancer cells, we observed G1 cell cycle arrest in our bladder cancer cell lines undergoing growth inhibition. In U251 human glioblastoma cells, an additional apoptosis-inducing stimulus was required to produce apoptosis (Davies et al., 1999a) . Thus, the function of the MMAC1/PTEN gene appears to vary in dierent cell types and may depend on interaction with other transductional pathways.
Failure to respond to chemotherapy due to the development of drug-resistant tumors is a signi®cant clinical problem (Pu et al., 1996) . Classic multidrug resistance (MDR) is associated with expression of the mdr-1 gene which encodes P-glycoprotein, a protein that actively pumps certain chemotherapeutic agents from the cell. However, other mechanisms of drug resistance also occurs such as those involving the DNA topoisomerase II gene, MDR-associated protein expression, and glutathione (Naito et al., 1995; Kim et al., 1995; Ahn et al., 1994) . We previously established and characterized the doxorubicin-resistant subline UM-UC-6dox (Shinohara et al., 1993; Usansky et al., 1991) . UM-UC-6dox is 6.7-fold more resistant to doxorubicin than its parental human bladder cancer cell line UM-UC-6, as calculated by the IC 50 ratio, and exhibits an atypical drug resistance pattern.
In this study, we demonstrated that, after infection with Ad-MMAC, UM-UC-6dox cells had 3.6 ± 4.2-fold greater chemosensitivity to doxorubicin (IC 50 = 1.44 mg/ml at 200 MOI) than did mock treated UM-UC-6dox cells (IC 50 =6.03 mg/ml) or control adenovirus infected cells (IC 50 =5.54 mg/ml at 200 MOI). Additionally, Ad-MMAC infection of UM-UC-6dox cells showed a synergistic eect with doxorubicin in causing cytotoxicity. Other forms of gene therapy, for example p53, have been shown to modulate sensitivity to DNA-damaging drugs, especially cisplatin (Fujiwara et al., 1994; Ogawa et al., 1997; Gurnani et al., 1999) . However, the mechanisms of this phenomenon are unknown. PI3'K and Akt/PKB have been shown to be involved in survival signaling with doxorubicin treatment of Ewing's sarcoma cells (Thakar et al., 1999) . Transfection of TC-32 Ewing sarcoma cells with Akt/ Chemosensitivity to doxorubicin in UM-UC-6dox cells after introduction of MMAC1/PTEN gene via an adenoviral procedure at dierent MOI compared with mock-or Ad-GFPinfected UM-UC-6dox cells. (a) Exposure to dierent concentration of doxorubicin with cell survival measured at 4 days, (b) Exposure to doxorubicin at 2 or 3 mg/ml with cell survival measured over 6 days. The cytotoxic activities were expressed as per cent survival, which was calculated as follows: experimental optical density/control optical density 6 100 (%). Control optical density was determined from wells in which target cells were incubated with medium alone. The IC 50 of Ad-MMAC infected UM-UC-6dox cells was signi®cantly dierent from that of mockor Ad-GFP-infected cells. P50.01, Student's t-test PKB expression vector inhibited doxorubicin-induced apoptosis. Our data suggest that the MMAC1/PTEN gene increases doxorubicin toxicity in drug resistant bladder cancer cells through the PI3'K signaling pathway, decreasing Akt/PKB phosphorylation.
These experiments indicate that MMAC1/PTEN plays a role in growth suppression and in enhancing chemosensitivity to doxorubicin and that the MMAC1/ PTEN gene and its pathways appear to be useful therapeutic targets in bladder cancer.
Materials and methods

Bladder cancer cell lines and adenovirus vectors
The human bladder cancer cell lines UM-UC-1, UM-UC-2, UM-UC-3, UM-UC-6, UM-UC-9, UM-UC-14, T24, and RT4 were cultured in Dulbecco's modi®ed Eagle's medium containing 10% heat-inactivated fetal bovine serum (FBS) at 378C in an atmosphere of 5% CO 2 . UM-UC-6dox, a doxorubicin resistant subline of UM-UC-6 selected in vitro by exposure to doxorubicin, was maintained in the same medium with the addition of 1 mg/dl doxorubicin (Shinohara et al., 1993) . Normal controls included primary culture of human urothelial cells from a patient without bladder cancer (NU) and the immortalized normal human urothelial cell line SV-HUC. NU and SV-HUC were grown in Keratinocyte-SFM and Ham's F-12 medium (Life Technologies, Rockville, MD) with 1% FBS, respectively.
A recombinant adenovirus containing wild-type MMAC1/ PTEN (Ad-MMAC) and a control adenovirus expressing the enhanced green¯uorescent protein (Ad-GFP) were used as described previously (Davies et al., 1999a) . The titers of Ad-MMAC and Ad-GFP were 1.7610 11 and 1.5610 11 plaque forming units (p.f.u.)/ml, respectively.
Cell proliferation assay
UM-UC-3 and T24 cells were plated at a density of 5610 4 cells per well into 35 mm six-well plates. The following day, cells were counted and infected with Ad-MMAC or Ad-GFP at the indicated MOI or mock-infected with culture medium alone. Viable cells were determined by trypan blue exclusion at the indicated time points.
Protein analysis
Subcon¯uent UM-UC-3, T24, and UM-UC-6dox cells were infected with Ad-MMAC or Ad-GFP. Twenty-four hours after infection, the cells were changed to serum-free medium. After another 24 h, the cells were harvested with or without stimulation with EGF at 50 ng/ml for 10 min, and cell lysates were obtained as previously described (Davies et al., 1999a) . For Western blot analysis, protein extracts of each sample (30 mg/lane) were electrophoretically separated and electrically transferred onto nitrocellulose. Membranes were incubated with antibodies against total and phosphorylatedspeci®c Akt/PKB (New England Biolabs Boston, MA, USA) and MMAC1/PTEN (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by horseradish peroxidase-conjugated secondary antibody. Protein-antibody complexes were detected by an enhanced chemiluminescence system (ECL-Plus; Amersham, Piscataway, NJ, USA) on X-ray ®lm (Amersham, Piscataway, NJ, USA).
Flow cytometry analysis of the cell cycle UM-UC-3 and T24 bladder cancer cells were seeded at 5610 5 cells in a 10-cm tissue culture dish and incubated overnight, followed by infection with Ad-MMAC or control Ad-GFP or mock-treated. Cells were maintained in medium supplemented with 10% FBS and harvested at various times thereafter. Cells were trypsinized, ®xed in 1% paraformaldehyde, and stored at 48C in 70% ethanol overnight. DNA staining with propidium iodide was then used to determine the cell cycle distribution, measuring at least 10 000 gated cells infected with Ad-MMAC or control Ad-GFP or mocktreated.
In vitro cytotoxicity assay A crystal violet assay was used to assess cell number as previously described (Kanamaru and Yoshida, 1989) . Brie¯y UM-UC-6dox bladder cancer cells were seeded in 96-well plates at a density of 5610 3 cells per well and were infected with Ad-MMAC or Ad-GFP at 100 and 200 MOI. Twentyfour hours after infection, medium containing dierent concentrations of doxorubicin HCl (Fujisawa USA, Inc., Deer®eld, IL, USA) was added. After 4 days of treatment with doxorubicin, the cells were ®xed with 1% glutaraldehyde for 15 min, stained with 0.5% crystal violet (Sigma, St Louis, MO, USA) for 15 min, washed with water for 10 min, and allowed to air dry overnight. Similarly, cytotoxicity and cell survival were determined at various time points up to 6 days after treatment with doxorubicin at the indicated concentrations. Sorenson's solution (30 mM trisodium citrate, 0.06% HCl, 47.5% ethanol) was added to elute the dye, and the optical density was read on a microplate autoreader (Bio-Tek Instruments, Winooski, VT, USA) at 540 nm. Absorbance values were normalized to the values obtained for the vehicletreated cells to determine the survival percentage. Each assay was performed in triplicate.
